Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, has expanded its drug product (DP) services offering by adding a new facility for quality control and bioanalytics at its DPS site in Basel (CH) to support its global DP capacity increase. 
 
The expansion includes 6000m² of state-of-the-art labs and office space to support early and late-stage clinical and commercial DP QC. The new facility allows DPS to double its capacity for the development and testing of parenteral dosage forms and strengthens existing DP capabilities offered from the Stücki Technology Park in Basel.
 
Peter Droc, Head of Drug Product Services, Lonza, said, “Expanding Lonza’s drug product capacity is a key enabler of our wider Biologics strategy to offer drug developers a seamless solution across modalities, from early development to drug substance and drug product manufacture. With the demand for drug product manufacturing continuing to increase, this new bioanalytics and QC facility will enable us to provide our customers with crucial manufacturing services for the delivery of life-saving medicines.”